Recbio has a high-value vaccine portfolio consisting of HPV vaccine candidates, COVID-19 vaccine candidates, shingles vaccine candidates, influenza vaccine candidates, adults TB vaccine candidates, etc. The core scientific team has more than 20 years of experience in the development and commercialization of innovative vaccines. Recbio is one of the few companies with commercial production capability for novel adjuvants that ha...
Recbio has a high-value vaccine portfolio consisting of HPV vaccine candidates, COVID-19 vaccine candidates, shingles vaccine candidates, influenza vaccine candidates, adults TB vaccine candidates, etc. The core scientific team has more than 20 years of experience in the development and commercialization of innovative vaccines. Recbio is one of the few companies with commercial production capability for novel adjuvants that have been approved by FDA for human use.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.